Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0250 7005 OR L773:1791 7530 srt2:(2000-2004)"

Sökning: L773:0250 7005 OR L773:1791 7530 > (2000-2004)

Sortera/gruppera träfflistan
  • Carlsson, Maria, 1958-, et al. (författare)
  • Treatment modality affects long-term quality of life in gynaecological cancer.
  • 2000
  • Ingår i: Anticancer Research. - The International Institute of Anticancer Research. - 0250-7005 .- 1791-7530. ; 20:1B, s. 563-568
  • Tidskriftsartikel (refereegranskat)abstract
    • In order to survey the side effects after cancer treatment, quality of life data were collected from females in clinical remission.MATERIALS AND METHODSThe study was cross-sectional; every patient that visited the outpatient clinic during a period of three months was asked to anonymously complete the EORTC QLQ-C30 questionnaire and five additional specific questions related to gynaecological cancer.RESULTSIn total, 235 patients (90%) returned the questionnaire. In general, both the levels of functioning and symptomatology were time-dependent. Patients with short treatment-free intervals reported more problems than the others. When using treatment modality as an independent variable in the statistical calculations, a treatment-related effect on functioning and symptomatology was demonstrated (p < 0.05 to p < 0.001). Patients previously treated with chemotherapy had poorer role- and cognitive functioning and more problems with fatigue, nausea, vomiting, dyspnoea, constipation and financial problems, compared with those not treated with chemotherapy (p < 0.05 to p < 0.01). Those patients who had been treated with external radiotherapy and/or brachytherapy had significantly more problems with flatulence and diarrhoea (p < 0.05 to p < 0.001). In conclusion, patients who underwent treatment for gynaecological cancer reported long-term side effects also many years after finishing treatment. The problems where related to treatment modality which should be considered, especially when planning adjuvant treatment.
  • Li, Li, et al. (författare)
  • Induction of apoptosis or necrosis in human endometrial cancer cells by 2-Methoxyestradiol
  • 2004
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 24:6, s. 3983-3990
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:We investigated the effects of 2methoxyestradiol (2-ME), an endogenous estrogenic metabolite, on human endometrial cancer HEC-1-A and RL-95-2 cell lines.MATERIALS AND METHODS:After exposure of HEC-1-A and RL-95-2 cells to 2-ME, the morphological changes were evaluated by acridine orange staining and transmission electron microscopy. Cell cycle progress, apoptosis and necrosis were assessed by flow cytometry, DNA fragmentation and Western blot.RESULTS:2-ME inhibited cell growth by blocking the S- and G2/M-phase in both cell lines, by inducing apoptosis in HEC-1-A cells and by causing necrosis in RL-95-2 cells. Apoptosis, on HEC-1-A cells, was accompanied by an increased expression of iNOS and STAT1. This apoptotic effect was prevented by the iNOS inhibitor 1400W and eliminated by the caspase inhibitor Z-VAD-FMK. Necrosis, on RL-95-2 cells, was due to a severe disruption of the mitochondrial membrane potential. 2-ME had no significant effect on normal human endometrial cells.CONCLUSION:The data suggest that 2-ME has an antitumor effect on human endometrial carcinoma cells (HEC-1-A and RL-95-2) and may contribute as a new therapeutic agent for endometrial cancer patients.
  • Nilsson, A, et al. (författare)
  • Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment
  • 2001
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 21:6A, s. 4087-4090
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:Alpha-interferon, a known inhibitor of angiogenesis and cell proliferation, is used in the standard treatment of patients with carcinoid tumors. We studied the levels of two angiogenic peptides (bFGF and VEGF) in sera from patients with carcinoid tumours before and during treatment with alpha-interferon. The aim was to investigate if the antitumoral effect of alpha-interferon in these patients could be at least in part explained by a reduction in the measured angiogenetic peptides.PATIENTS AND METHODS:Sera from 29 patients with carcinoid tumours were collected before and during alpha-interferon treatment and analyzed using commercially available ELISA-kits.RESULTS:Interferon alpha treatment did not cause reduction of bFGF and VEGF levels in serum from patients with carcinoid tumours. In fact there was no correlation between changes in bFGF or VEGF levels and treatment effect.CONCLUSION:The action of alpha-interferon does not seem to be mediated by bFGF or VEGF in patients with carcinoid tumours. If alpha-interferon has an anti-angiogenic effect in this patient group, it is probably mediated by angiogenic peptides other than bFGF and VEGF.
  • Orlova, Anna, et al. (författare)
  • Targeting against epidermal growth factor receptors : Cellular processing of astatinated EGF after binding to cultured carcinoma cells
  • 2004
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 24:6, s. 4035-4042
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:The alpha-emitting nuclide 211At is of great interest for radionuclide therapy when coupled to a tumor-targeting biomolecule, e.g. epidermal growth factor (EGF) the receptors of which are overexpressed in many malignancies. However, almost no information concerning the cellular processing of astatinated targeting agents is available.MATERIALS AND METHODS:We indirectly astatinated EGF ([211At]-benzoate-EGF) and studied its cellular processing in A-431 carcinoma cells in comparison with data concerning [125I]-benzoate-EGF.RESULTS: The biological half-life of astatine (3.5 h) was longer than the half-life of the iodine label (1.5 h). The increase of the half-life was due to longer retention of the internalised astatine radioactivity. The maximum accumulation for the astatine label occurred later (4-6h) than that for the iodine label (2-4h), indicating a slower excretion of astatine that was confirmed in experiment with 211At/1251-benzoate-EGF.CONCLUSION:The long retention of astatine might be advantageous for radionuclide therapy.
  • Simonsen, Lena E., et al. (författare)
  • Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats
  • 2000
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 20:3A, s. 1519-1525
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMTo study the effects of single and fractionated doses of 5-fluorouracil and epirubicin on the leukocyte counts in rats.METHODSSix different dosing patterns of each drug were injected within one day. The leukocytes were followed for 11-15 days. Pharmacokinetic models were developed using NONMEM. Quantitative and qualitative pharmacokinetic-pharmacodynamic relationships were investigated.RESULTSA one-compartment model with non-linear elimination described 5-fluorouracil pharmacokinetics and a three-compartment model described epirubicin concentration data. Sigmoidal or basic Emax-models quantified the relationships between individual AUCs and decreases in leukocytes, for both drugs. Similar relationships between AUC and toxicity were found, regardless of whether the drugs were given as single or fractionated doses.CONCLUSIONQuantitative relationships between AUC and the effect on leukocytes were established for 5-fluorouracil and epirubicin. However, no schedule dependence was indicated for the schedules used in the study.
  • Wymenga, Feng, et al. (författare)
  • Uptake of 14C- and 11C-labeled glutamate, glutamine and aspirtate in vitro and in vivo
  • 2000
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 20:1A, s. 251-256
  • Tidskriftsartikel (refereegranskat)abstract
    • To explore their potential use as in vivo tracers, the uptake of the amino acids glutamine, glutamate and aspartate, labeled with 11C or 14C, was evaluated in tumor cell aggregates, in vivo in rats and a few pilot studies with positron emission tomography (PET) in patients. The uptake in aggregates increased linearly with time, and was competitively inhibited by the same amino acids. The uptake of 14C-glutamate in carcinoid cells (BON) was inhibited by cystine but not by aspartate, contrary to the result in neuroblastoma (LAN). 6-Diazo-oxy-L-norleucine (a glutamine analogue) and Substance P had different effect on the uptake of glutamate in different cells. The metabolic fate of 14C-glutamate was evaluated with protein separation and with HPLC. The in vivo distribution in rats showed the highest uptake of 11C-glutamine and 11C-glutamate in pancreas and kidney, and of 11C-aspartate in the lung. In the human studies with PET, pancreas had the highest uptake followed by kidney with 11C-glutamate, and followed by spleen with 11C-aspartate. A primary pancreas tumour and metastases in liver were difficult to identify except in one case.
  • Andersson, Håkan, 1944-, et al. (författare)
  • Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
  • 2001
  • Ingår i: Anticancer research. - 0250-7005. ; 21:1A, s. 409-12
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the present study was to compare the therapeutic efficacy of the alpha-emitter Astatine-211 with the beta-emitter Iodine-131 bound to the specific monoclonal antibody MOv18. The measurements were performed in an ovarian cancer cell line (NIH:OVCAR 3) growing intraperitoneally in nude mice. Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I (5100-6200 kBq). The pharmacokinetics and biodistribution of labelled antibody in tumour-free animals were studied and the resulting bone marrow dose was estimated. When the mice were treated with 211At-labelled antibody 9 out of 10 mice were free of macro- and microscopic tumour compared to 3 out of 10 when Iodine-131 was used. The equivalent dose to the bone marrow was 2.4-3.1 Sv from 211At- and 3.4-4.1 Sv from 131I-irradiation. The therapeutic efficacy of 211At-labelled specific antibody is very good and, at approximately equivalent bone marrow doses, better than that of 131I.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (122)
konferensbidrag (12)
Typ av innehåll
refereegranskat (117)
övrigt vetenskapligt (17)
Rubio, CA, (18)
Hultborn, Ragnar, 19 ... (6)
Bergqvist, M. (6)
Nilsson, A (5)
Nilsson, S. (5)
Biberfeld, P, (4)
visa fler...
Lewensohn, R., (4)
Auer, G, (4)
Lennernäs, Bo, 1963- ... (4)
Palm, Stig, 1964-, (4)
Dobra, K, (4)
Stenram, Unne, (3)
Landberg, Göran (3)
Kato, Y. (3)
Hogmo, A. (3)
Tribukait, B (3)
Jonsson, G (3)
Dalianis, T, (3)
Glimelius, B (3)
Persson, C., (2)
Rydén, Lisa, (2)
Chandra, A. (2)
Naredi, Peter, 1955- ... (2)
Chandra, P (2)
Linde, A (2)
Urassa, W (2)
Tolmachev, Vladimir, (2)
Tranberg, Karl-Göran ... (2)
Berglund, A. (2)
Strang, Peter, 1957- ... (2)
Paulie, S (2)
Hellstrand, Kristoff ... (2)
Friesland, S, (2)
Jaramillo, E (2)
Larsson, A, (2)
Orlova, Anna, (2)
Eriksson, Barbro, (2)
Lofberg, R, (2)
Grandien, A (2)
Lagergren, J, (2)
Eriksson, A (2)
Linder, S, (2)
Marquez, M, (2)
Holmberg, AR (2)
Kaaya, E (2)
Janciauskiene, Sabin ... (2)
Wågsäter, Dick, (2)
Hauzenberger, D (2)
Befrits, R. (2)
visa färre...
Karolinska Institutet (86)
Lunds universitet (19)
Göteborgs universitet (18)
Uppsala universitet (8)
Linköpings universitet (8)
Umeå universitet (7)
visa fler...
Högskolan i Jönköping (3)
Kungliga Tekniska Högskolan (1)
Högskolan i Halmstad (1)
visa färre...
Engelska (134)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (53)
Naturvetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy